TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15923802
Drug: Single high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single high-dose chemotherapy (S)
Study: 6480458
Drug: Ro-03-8799 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro-03-8799 at 1 g/m2
Study: 29771017
Drug: Intranasal corticosteroids
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal corticosteroids combined with normal saline nasal irrigation
Study: 29771017
Drug: Intranasal corticosteroids
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal corticosteroids only
Study: 29771017
Drug: Intranasal corticosteroids
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal corticosteroids combined with antihistamines
Study: 24727364
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT-AN)
Study: 19773728
Drug: Transurethral Microwave
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transurethral Microwave Therapy (TUMT)
Study: 19773728
Drug: Holmium Laser
Normalized name: holmium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Holmium Laser Therapy
Study: 18991132
Drug: Conduct disorder
Normalized name: Cystic fibrosis transmembrane conductance regulator
DrugBank: Cystic fibrosis transmembrane conductance regulator (DB15180)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conduct disorder in youth with high levels of hyperactivity symptoms, poor school functioning, and peer alcohol and drug use
Study: 12608319
Drug: Photodynamic Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic Therapy (PDT) with verteporfin
Study: 10666802
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil 30 mg/kg/day for 14 days
Study: 2216203
Drug: Weekly membrane
Normalized name: Weekly Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly membrane stripping beginning at 38 weeks
Study: 202160
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (400 mg/day)
Study: 9683924
Drug: Angiotensin I
Normalized name: ANGIOTENSIN I
DrugBank: Angiotensin 1-7 (DB11720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin I (AngI) infusion at doses of 0.3, 1, and 3 pmol x kg‐1 x min‐1
Study: 9683924
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II (AngII) infusion at doses of 0.3, 1, and 3 pmol x kg‐1 x min‐1
Study: 7706607
Drug: Logistic regression
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Logistic regression model including serum albumin, body mass index, renal disease, Katz Index of Activities of Daily Living score, weight loss
Study: 2785775
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with dog dander and hair extract (n = 35)
Study: 2785775
Drug: Maintenance treatment
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance treatment (n = 15)
Study: 11856774
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (n = 12)
Study: 27836809
Drug: Hecolin vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hecolin vaccine (1 to 3 doses)
Study: 26515417
Drug: no antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: no antiplatelet medication (controls)
Study: 19454355
Drug: Sibutramine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine (10 mg daily) with lifestyle change
Study: 16458640
Drug: 400 microg
Normalized name: Fentanyl 400 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 microg buccal misoprostol
Study: 15298564
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g fish oil capsules (containing 3.7 g n‐3 PUFA)
Study: 15298564
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g olive oil capsules
Study: 8656678
Drug: Low-dose all-trans
Normalized name: all-trans-retinol
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose all-trans retinoic acid (ATRA) at 15-20 mg/m2/day
Study: 8656678
Drug: Low-dose all-trans
Normalized name: all-trans-retinol
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose all-trans retinoic acid (ATRA)
Study: 8656678
Drug: High-dose all-trans
Normalized name: all-trans-retinol
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose all-trans retinoic acid (ATRA)
Study: 6807435
Drug: Sulpiride 50
Normalized name: sulpiride 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride 50 mg thrice daily for four weeks
Study: 9023068
Drug: Individual Drug
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual Drug Counseling (IDC)
Study: 25422247
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia combined with SGB (0.12 mL/kg 1% lidocaine 10 min before induction)
Study: 25422247
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia (group N)
Study: 22500884
Drug: Goserelin (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin (3.6 mg) + Bicalutamide (50 mg for 28 days)
Study: 17623816
Drug: Pioglitazone (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (45 mg for 30 days)
Study: 2910782
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of cisplatin 50 mg/m2 over 24 hr
Study: 2910782
Drug: Rapid infusion
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid infusion of cisplatin 50 mg/m2 at a rate of 1 mg/min
Study: 16015688
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) treatment after 6 months
Study: 12453861
Drug: IL‐2 9
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL‐2 9 MU subcutaneously twice daily on days 4‐8 and 25‐29, and once daily on days 11‐15 and 32‐36; IFN‐alpha‐2b 5 MU subcutaneously on days 1‐3 and then daily to day 43; Histamine 1 mg subcutaneously twice daily starting on day 4
Study: 7856295
Drug: Aerosol inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol inactivated split influenza virus vaccine
Study: 7856295
Drug: Cold-adapted reassortant
Normalized name: human-bovine reassortant rotavirus strain G4 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold-adapted reassortant live influenza virus vaccine
Study: 7856295
Drug: Mucosal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mucosal administration of inactivated influenza virus vaccine
Study: 2536803
Drug: Two-hour infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-hour infusion of cisplatin
Study: 2536803
Drug: 24-hour infusion
Normalized name: respiratory syncytial virus pre-fusion F protein, recombinant 0.24 MG/ML [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour infusion of cisplatin
Study: 1060146
Drug: Active immunotherapy
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active immunotherapy after chemoradiotherapy
Study: 1060146
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no active immunotherapy)
Study: 1060146
Drug: Immunotherapy after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy after chemotherapy
Study: 1060146
Drug: Immunotherapy before
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy before chemotherapy
Study: 11473870
Drug: Lactated Ringers
Normalized name: lactated ringers
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringers solution (RL), n = 21
Study: 31315885
Drug: Repeated immunization
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated immunization with a Listeria monocytogenes‐based vaccine encoding for mesothelin in combination with a GM‐CSF‐transfected allogeneic pancreatic cell vaccine
Study: 29648860
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (1‐hour video; n = 10)
Study: 20416137
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) consisting of exposure and response prevention (EX/RP)
Study: 16103696
Drug: Hand rubbing
Normalized name: ALCOHOL 0.8 TOPICAL SPRAY [Hand Rub]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hand rubbing with alcohol-based solutions
Study: 12482009
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care program involving individualized health promotion by a research pharmacist with monthly appointments for 6 months.
Study: 7657446
Drug: 4% nicotinamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% nicotinamide gel
Study: 2697239
Drug: Labetalol 10
Normalized name: HCTZ 25/LABETALOL 100MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol 10 mg
Study: 2697239
Drug: Labetalol 5
Normalized name: LABETALOL 5MG/ML INJ CARPUJECT 4ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol 5 mg
Study: 31543950
Drug: Menopausal hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Menopausal hormone treatment (MHT) started within 5 to 10 years of menopause
Study: 31543950
Drug: Estrogen treatment
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen treatment (ET) for women undergoing premature menopause
Study: 31543950
Drug: Menopausal hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Menopausal hormone treatment (MHT) for normal women
Study: 26413574
Drug: 1500 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg/day Korean red ginseng for 4 weeks
Study: 26413574
Drug: 3000 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3000 mg/day Korean red ginseng for 4 weeks
Study: 26413574
Drug: 160 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg/day Ginkgo biloba extract for 4 weeks
Study: 22077928
Drug: Soy isolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isolate protein supplement (24 g daily for 8 weeks)
Study: 22077928
Drug: Milk protein
Normalized name: Milk protein
DrugBank: Casein (DB10516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk protein supplement (24 g daily for 8 weeks)
Study: 19917449
Drug: Beta-glucan (5.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-glucan (5.5 g)
Study: 19917449
Drug: Beta-glucan (2.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-glucan (2.2 g to 5.5 g)
Study: 19917449
Drug: Beta-glucan (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-glucan (various doses)
Study: 17030521
Drug: Caldaret 57.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caldaret 57.5 mg (lower dose)
Study: 17030521
Drug: Caldaret 172.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caldaret 172.5 mg (higher dose)
Study: 8858533
Drug: Chemotherapy (combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (combinations of Adriamycin and Dacarbazine or Ifosfamide and Mesna)
Study: 8858533
Drug: Immunotherapy (interferon‐alpha)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (interferon‐alpha)
Study: 6391162
Drug: Low-sucrose diet
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-sucrose diet (less than 3 g of sucrose)
Study: 6391162
Drug: High-sucrose diet
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-sucrose diet (220 g of sucrose)
Study: 6391162
Drug: Intermediate-sucrose diet
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermediate-sucrose diet (120 g of sucrose)
Study: 6391162
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (120 g of sucrose and 50 percent carbohydrate)
Study: 31986325
Drug: Topical ozone
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ozone therapy (ozone hydrotherapy followed by ozonated oil)
Study: 27741414
Drug: Topical ozone
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ozone therapy
Study: 22153696
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids 2 g daily for 2 months
Study: 22153696
Drug: Fenofibrate 160
Normalized name: fenofibrate 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 160 mg daily for 2 months
Study: 7036726
Drug: Diltiazem 120
Normalized name: diltiazem 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 120 mg and 240 mg
Study: 29463913
Drug: Oxycodone 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 5.0 mg
Study: 29463913
Drug: Oxycodone 2.5
Normalized name: oxycodone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 2.5 mg + active cannabis (5.6% THC)
Study: 29463913
Drug: Oxycodone 2.5
Normalized name: oxycodone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 2.5 mg
Study: 29463913
Drug: Oxycodone +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone + cannabis
Study: 20142658
Drug: Recombinant activated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant activated factor VII (rFVIIa) at a median dose of 81.5 microg/kg
Study: 18566863
Drug: Specific oral
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific oral anticoagulation treatment educational program
Study: 16629421
Drug: Interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1a (IFNbeta-1a, Avonex) 60 microg weekly intramuscular injections for 24 months
Study: 14762699
Drug: Iodine-131 therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodine-131 therapy (1.8-10.4 GBq single activity, 5.5-43.7 GBq total activity) after total thyroidectomy and lymph node dissection if applicable
Study: 4039155
Drug: Flupirtine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupirtine (100 mg, 3 consecutive doses)
Study: 4039155
Drug: Pentazocine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine (50 mg, single dose)
Study: 2903762
Drug: Mifentidine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifentidine 20 mg
Study: 2906876
Drug: Mifentidine 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifentidine 40 mg
Study: 2906876
Drug: Mifentidine 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifentidine 80 mg
Study: 29614679
Drug: Composite supplement
Normalized name: DRESSING,COMPOSITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Composite supplement containing astaxanthin and sesamin (AS)
Study: 24563922
Drug: Chloroprocaine (CP)
DrugBank: Chloroprocaine (DB01161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroprocaine (CP) 40 mg intrathecally with 500 ml pre-load (CP+)
Study: 24563922
Drug: Chloroprocaine (CP)
DrugBank: Chloroprocaine (DB01161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroprocaine (CP) 40 mg intrathecally without pre-load (CP−)
Study: 24563922
Drug: Lidocaine (L)
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine (L) 60 mg intrathecally with 500 ml pre-load (L+)
Study: 24563922
Drug: Lidocaine (L)
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine (L) 60 mg intrathecally without pre-load (L−)
Study: 14633959
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus somatostatin 250 microg given immediately after diagnostic cholangiopancreatography
Study: 10966906
Drug: Glucose (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (50 g carbohydrate)
Study: 10966906
Drug: Potatoes (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potatoes (50 g carbohydrate)
Study: 10966906
Drug: Barley (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barley (50 g carbohydrate)
Study: 8470531
Drug: Scopolamine (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (two pieces of Scopoderm-TTS patches)
Study: 3511703
Drug: Hypocaloric diet
Normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypocaloric diet combined with antiandrogenic therapy (cyproterone acetate, 50 mg/day, plus ethinyl estradiol, 0.05 mg/day)
Study: 3511703
Drug: Hypocaloric diet
Normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypocaloric diet without antiandrogenic therapy
Study: 20413988
Drug: Probiotic Escherichia
Normalized name: escherichia coli
DrugBank: Escherichia coli (DB16539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic Escherichia coli strain administered (1 mL within 48 hours after birth, then 3 times a week for 4 weeks)
Study: 18687167
Drug: Amino-bisphosphonates treatment
Normalized name: (4-amino-1-hydroxybutylidene)bisphosphonic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino-bisphosphonates treatment
Study: 1488514
Drug: Acarbose 100
Normalized name: acarbose 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose 100 mg (t.i.d.)
Study: 6416184
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MMC and Futraful
Study: 28193189
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose DHA supplementation (1000 mg DHA/d)
Study: 28193189
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (200 mg DHA/d from prenatal supplement)
Study: 19796455
Drug: Dutasteride 3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride 3.5 mg and bicalutamide 50 mg once daily
Study: 19796455
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and bicalutamide 50 mg once daily
Study: 8095008
Drug: Later zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Later zidovudine therapy
Study: 8095008
Drug: Masked therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Masked therapy continuation
Study: 8095008
Drug: Unmasked treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unmasked treatment and follow-up
Study: 3680580
Drug: Nalmefene 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalmefene 50 mg
Study: 3680580
Drug: Nalmefene 100
Normalized name: nalmefene 100 MCG in 1 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalmefene 100 mg
Study: 3680580
Drug: Nalmefene 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalmefene 200 mg
Study: 3680580
Drug: Nalmefene 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalmefene 300 mg
Study: 3680580
Drug: Nalmefene 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalmefene 20 mg q12h for 7 days
Study: 26509991
Drug: Laser-Lok implants
Normalized name: Lokara
DrugBank: Desonide (DB01260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Laser-Lok implants (LL)
Study: 26509991
Drug: Non-Laser-Lok implants
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-Laser-Lok implants (NLL)
Study: 23398493
Drug: Combined cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined cognitive behavioral therapy (CBT)
Study: 22026413
Drug: Intraarticular ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular ropivacaine infusion (0.5%, 2 mL/h)
Study: 22026413
Drug: Extraarticular ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extraarticular ropivacaine infusion (0.5%, 2 mL/h)
Study: 17297828
Drug: 40 mL
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mL of 1% mepivacaine with adrenaline plus 4 mL of NaHCO3 and 1 mL of saline (Group II)
Study: 17297828
Drug: 40 mL
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mL of 1% mepivacaine with adrenaline plus 4 mL of NaHCO3 and 150 microg of clonidine (Group IV)
Study: 17297828
Drug: 40 mL
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mL of 1% mepivacaine with 150 microg of clonidine plus 4mL of saline (Group III)
Study: 17297828
Drug: 40 mL
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mL of 1% mepivacaine with adrenaline plus 5 mL of saline (Group I - Control)
Study: 11119051
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) as add-on therapy
Study: 2586439
Drug: Chemo-immunotherapy (CDDP+VDS,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemo-immunotherapy (CDDP+VDS, IL2+LAK cells)
Study: 2586439
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro stimulated LAK cells (St-LAK) administered locally
Study: 2586439
Drug: LAK-BAI (bronchial
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAK-BAI (bronchial arterial infusion) combined with radiation therapy
Study: 2586439
Drug: Chemotherapy (CDDP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CDDP + VDS)
Study: 31475938
Drug: Manual posterior
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual posterior capsule stretching (Group 2, n=27)